ENLV - Company ID 0001596812
The table below shows Enlivex Therapeutics Ltd.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.89M | $3.30M | $813.00K | $49.95M | $11.20M | $5.67M |
| Short-term investments | $198.00K | $198.00K | $5.11M | $62.92M | $62.92M | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $1.74B |
| $25.99M |
| $33.76M |
| $52.33M |
| $86.44M |
| $38.12M |
| Property, plant & equipment | $361.00K | $625.00K | $1.54M | $9.88M | $2.53M | $1.48M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $2.33B | $27.69M | $36.83M | $67.64M | $95.15M | $40.36M |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $9.02M | $3.80M | $6.06M | $6.61M | $4.72M | $4.37M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $392.05M | $4.10M | $6.75M | $10.80M | $10.11M | $4.87M |
| Retained earnings | $1.11B | -$127.11M | -$112.09M | -$83.03M | -$51.97M | -$37.50M |
| Total equity | $1.93B | $23.59M | $30.08M | $56.84M | $85.04M | $35.49M |